Advertisement

Topics

Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

07:49 EDT 31 Jul 2018 | Pharmaceutical Business Review

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the

The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.

Original Article: Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...